Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 314)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Celecoxib |
Approved, Investigational |
Phase 4 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
2 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206 |
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Fluoromethyl hexafluoroisopropyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
HFE-347MMZ1
MR6S4
MR-6S4
Sevofluran
SEVOFLURANE
|
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevorane
SOJOURN
Ultane
|
|
3 |
|
Desflurane |
Approved |
Phase 4 |
|
57041-67-5 |
42113 |
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
(±)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,2,2,2-Tetrafluoroethyl difluoromethyl ether
Baxter anaesthesia brand OF desflurane
Baxter brand OF desflurane
DESFLURANE
DESFLURANO
Desflurano [INN-Spanish]
|
DESFLURANUM
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
HFE-236EA2
I-653
Ohmeda brand OF desflurane
Suprane
Zeneca brand OF desflurane
|
|
4 |
|
Etomidate |
Approved |
Phase 4 |
|
33125-97-2 |
667484 |
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylic acid
(+)-Ethyl 1-(a-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(a-methylbenzyl)imidazole-5-carboxylic acid
(+)-Ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(α-methylbenzyl)imidazole-5-carboxylic acid
(+)-Etomidate
(+)-Etomidic acid
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-(+)-1-(a-Methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(a-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-(+)-1-(Α-methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(Α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylate ethyl ester
|
(R)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylate ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
AMIDATE
D-ETOMIDATE
Ethomidate
ETOMIDATE
Etomidato
Etomidatum
Etomidic acid
Hypnomidate
R 16659
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid
Radenarkon
|
|
5 |
|
Meperidine |
Approved |
Phase 4 |
|
57-42-1 |
4058 |
Synonyms:
ALODAN
Centralgin
Demarol
Demerol
Demerol®|meperidine
Dispadol
Dolantin
Dolargan
Dolcontral
Dolin
Dolosal
Dolsin
IDS-NP-001
Isonipecain
Isonipecaine
ISONIPECAÏNE
Lidol
Lydol
MEPADIN
Meperidina
MEPERIDINE
Meperidine Hcl
|
Meperidine hydrochloride
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
Nemerol
Operidine
Operidine epj I
Operidine epj-I
Petantin
Pethanol
PETHIDIN
Pethidine
PÉTHIDINE
Pethidine DBL
Pethidineter
PETHIDINUM
PETIDINA
PETYDYNA
Phetidine
Piperosal
Pipersal
Piridosal
|
|
6 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
Buccolam
Buccolam®|Dormicum®|Nayzilam®|USL261 (nasal spray formulation)|Versed®
Dea no. 2884
Dormicum
Hydrochloride, midazolam
Maleate, midazolam
Mezolam
Midazolam
Midazolam base
MIDAZOLAM CIV
|
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Nayzilam
USL261
USL-261
Versed
|
|
7 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 4 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
8 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
9 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
10 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
11 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
12 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
13 |
|
Anesthetics, Inhalation |
|
Phase 4 |
|
|
|
14 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
15 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
17 |
|
Bismuth |
|
Phase 4 |
|
7440-69-9 |
105143 |
Synonyms:
Bi
Bi(3+)
Bismuth(III) cation
|
Bismuth-209
Bisumth(3+) ion
|
|
18 |
|
Anesthetics |
|
Phase 4 |
|
|
|
19 |
|
Analgesics |
|
Phase 4 |
|
|
|
20 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
21 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
23 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
24 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
25 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
26 |
|
Narcotics |
|
Phase 4 |
|
|
|
27 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
28 |
|
Ulipristal acetate |
|
Phase 4 |
|
126784-99-4 |
13559282 130904 |
Synonyms:
(11BETA,17ALPHA)-17-ACETYL-11-[4-(DIMETHYLAMINO)PHENYL]-3-OXOESTRA-4,9-DIEN-17-YL ACETATE
14-Acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-1,6-dien-14-yl acetic acid
17-ACETOXY-11-(4-N,N-DIMETHYLAMINOPHENYL)PREGNA-4,9-DIENE-3,20-DIONE
CDB 2914
CDB-2914
CDB-2914|EllaOne®|VA2914
ELLA
ELLAONE
|
ESMYA
PGL-4001
RTI-3021-012
ULIPRISTAL ACET
ULIPRISTAL ACETATE
Ulipristal acetic acid
VA2914
VA-2914
|
|
29 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
30 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
31 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
32 |
|
Levamisole |
Approved, Investigational, Vet_approved, Withdrawn |
Phase 3 |
|
14769-73-4 |
26879 |
Synonyms:
(-)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
(-)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
(-)-Tetramisole
(S)-(-)-Levamisole
(S)-(-)-Tetramisole
(S)-2,3,5,6-Tetrahydro-6-phenylimidazo[2,1-b]thiazole
Decaris
Dekaris
DL-Tetramisol
DL-Tetramisole
ERGAMISOL
Hydrochloride, levamisole
Ketrax
Lepuron
|
Levamisol
Levamisole
Levamisole hydrochloride
Levamisolum
Levomysol
Levotetramisole
Levovermax
L-Tetramisole
Phenyl imidothiazole
R-12564
Solaskil
TCMDC-125847
Totalon
Wormicid
|
|
33 |
|
Cemiplimab |
Approved, Investigational |
Phase 3 |
|
1801342-60-8 |
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
34 |
|
Infigratinib |
Approved, Investigational |
Phase 3 |
|
872511-34-7 |
53235510 |
Synonyms:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
BGJ 398|BGJ-398|BGJ398|NVP-BGJ398|Truseltiq®
BGJ398
|
BGJ-398
INFIGRATINIB
MVP-BGJ398
NVP-BGJ398
|
|
35 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
36 |
|
Lenvatinib |
Approved, Investigational |
Phase 3 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
37 |
|
Capecitabine |
Approved, Investigational |
Phase 3 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
38 |
|
Citalopram |
Approved |
Phase 3 |
|
59729-32-7, 59729-33-8 |
2771 |
Synonyms:
[<sup>3</sup>H]-citalopram
Akarin
Bonitrile
Celapram
Celexa
Celexa®|Cipramil®|LU-10171B
Celius
Ciazil
Cilift
Cipram
CIPRAMIL
Ciprapine
Citabax
Citadur
Citalec
Citalopram
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
Citopam
Citox
|
Citrol
Cytalopram
Dalsan
Elopram
Escitalopram
Escitalopram oxalate
Humorup
Lexapro
LU 10-171-B
LU-10-171-B
Nitalapram
Oropram
PAXORAN
Pramcit
Recital
Seropram
Talam
Talohexal
Temperax
Vodelax
Zentius
Zetalo
|
|
39 |
|
Dexetimide |
Withdrawn |
Phase 3 |
|
21888-98-2 |
30843 |
Synonyms:
(+)-BENZETIMIDE
(+)-benzetimide|R 16470|Tremblex®
Dexetimida
DEXETIMIDE
|
Dexetimidum
R 16470
R-16470 [AS HYDROCHLORIDE]
TREMBLEX
|
|
40 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
41 |
|
FOLFIRINOX |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
43 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
44 |
|
Emetics |
|
Phase 3 |
|
|
|
45 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
46 |
|
Tin Fluorides |
|
Phase 2, Phase 3 |
|
|
|
47 |
|
Anthelmintics |
|
Phase 3 |
|
|
|
48 |
|
Albumin-Bound Paclitaxel |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
Antimitotic Agents |
|
Phase 2, Phase 3 |
|
|
|
50 |
|
Tubulin Modulators |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 667)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial |
Unknown status |
NCT00746538 |
Phase 4 |
|
2 |
Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) |
Unknown status |
NCT00797121 |
Phase 4 |
|
3 |
Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial |
Unknown status |
NCT01642875 |
Phase 4 |
|
4 |
Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study |
Unknown status |
NCT02174575 |
Phase 4 |
Sevoflurane;Desflurane |
5 |
Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. |
Unknown status |
NCT01111591 |
Phase 4 |
Cox2 inhibitor (Celecoxib) |
6 |
Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial |
Completed |
NCT00721175 |
Phase 4 |
|
7 |
Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) |
Completed |
NCT02027311 |
Phase 4 |
Etomidate;Midazolam;Meperidine |
8 |
Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors |
Completed |
NCT00168987 |
Phase 4 |
oral nutritional supplement rich in eicosapentanoic acid |
9 |
Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. |
Completed |
NCT00280709 |
Phase 4 |
|
10 |
Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy |
Completed |
NCT01256047 |
Phase 4 |
|
11 |
Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy |
Completed |
NCT01256034 |
Phase 4 |
|
12 |
Cholangiocarcinoma Treatment With Radiofrequency Ablation or Photodynamic Therapy: a Randomized Controlled Trial |
Recruiting |
NCT05551299 |
Phase 4 |
Photosensitizer |
13 |
Recombinant Human Adenovirus Type 5 Combined With Hepatic Artery Infusion Chemotherapy of FOLFOX in Patients With Intrahepatic Mass-forming Cholangiocarcinoma: a Single-site, Single-arm, Prospective Study |
Not yet recruiting |
NCT05124002 |
Phase 4 |
Recombinant Human Adenovirus Type 5;HAIC of FOLFOX |
14 |
Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma |
Unknown status |
NCT03771846 |
Phase 3 |
irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin |
15 |
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma |
Unknown status |
NCT02798510 |
Phase 3 |
capecitabine;gemcitabine |
16 |
Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial |
Unknown status |
NCT02108145 |
Phase 2, Phase 3 |
|
17 |
Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma |
Unknown status |
NCT02548195 |
Phase 3 |
oxaliplatin and gemcitabine;capecitabine |
18 |
Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. |
Unknown status |
NCT01755013 |
Phase 2, Phase 3 |
|
19 |
A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma |
Unknown status |
NCT01739465 |
Phase 2, Phase 3 |
|
20 |
Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial |
Unknown status |
NCT00653978 |
Phase 3 |
|
21 |
Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency |
Unknown status |
NCT03345303 |
Phase 3 |
Bortezomib |
22 |
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma |
Unknown status |
NCT01470443 |
Phase 3 |
Oxaliplatin |
23 |
A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy |
Unknown status |
NCT00809081 |
Phase 3 |
|
24 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation |
Completed |
NCT02989857 |
Phase 3 |
AG-120;Placebo |
25 |
Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control |
Completed |
NCT00869635 |
Phase 3 |
S-1 Chemotherapy |
26 |
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. |
Completed |
NCT01926236 |
Phase 3 |
L-folinic acid;5 FU;Oxaliplatin |
27 |
Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study |
Completed |
NCT00513539 |
Phase 3 |
porfimer sodium |
28 |
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours |
Completed |
NCT02591030 |
Phase 2, Phase 3 |
GEMCIS;mFolfirinox |
29 |
Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study |
Completed |
NCT00262769 |
Phase 3 |
cisplatin;gemcitabine hydrochloride |
30 |
A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer |
Completed |
NCT00363584 |
Phase 3 |
capecitabine |
31 |
Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract |
Completed |
NCT00304135 |
Phase 2, Phase 3 |
cisplatin;gemcitabine hydrochloride;oxaliplatin |
32 |
Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts |
Completed |
NCT01313377 |
Phase 3 |
gemcitabine hydrochloride;oxaliplatin |
33 |
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma |
Completed |
NCT01640522 |
Phase 3 |
|
34 |
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies |
Completed |
NCT02349412 |
Phase 3 |
|
35 |
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) |
Recruiting |
NCT03656536 |
Phase 3 |
Pemigatinib;Gemcitabine;Cisplatin |
36 |
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 |
Recruiting |
NCT04093362 |
Phase 3 |
TAS-120;Cisplatin/Gemcitabine |
37 |
A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
Recruiting |
NCT04669496 |
Phase 2, Phase 3 |
Neoadjuvant treatment |
38 |
Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma |
Recruiting |
NCT02773485 |
Phase 3 |
Systemic chemotherapy |
39 |
The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study |
Recruiting |
NCT03940378 |
Phase 3 |
Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules |
40 |
Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma |
Recruiting |
NCT04961970 |
Phase 3 |
oxaliplatin , fluorouracil, and leucovorin;gemcitabine and cisplatin |
41 |
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) |
Recruiting |
NCT02170090 |
Phase 3 |
Gemcitabine;Cisplatin;Capecitabine |
42 |
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors |
Recruiting |
NCT04157985 |
Phase 3 |
Continue PD-1/PD-L1 Inhibitors treatment |
43 |
Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection |
Recruiting |
NCT03779035 |
Phase 3 |
Gemcitabine;Capecitabine |
44 |
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
Active, not recruiting |
NCT03768414 |
Phase 3 |
Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel |
45 |
Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma |
Active, not recruiting |
NCT03086993 |
Phase 2, Phase 3 |
Cisplatin and Gemcitabine |
46 |
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial |
Active, not recruiting |
NCT03773302 |
Phase 3 |
BGJ398;Gemcitabine;Cisplatin |
47 |
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma |
Active, not recruiting |
NCT02807181 |
Phase 2, Phase 3 |
Cisplatin-gemcitabine |
48 |
Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma |
Active, not recruiting |
NCT02482454 |
Phase 2, Phase 3 |
|
49 |
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer |
Active, not recruiting |
NCT04066491 |
Phase 2, Phase 3 |
M7824;Placebo;Gemcitabine;Cisplatin |
50 |
Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial |
Active, not recruiting |
NCT02853474 |
Phase 3 |
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
|